Literature DB >> 16041556

Treatment of neuroendocrine cancer metastatic to the liver: the role of ablative techniques.

T D Atwell1, J W Charboneau, F G Que, J Rubin, B D Lewis, D M Nagorney, M R Callstrom, M A Farrell, H C Pitot, T J Hobday.   

Abstract

Carcinoid tumors and islet cell neoplasms are neuroendocrine neoplasms with indolent patterns of growth and association with bizarre hormone syndromes. These tumors behave in a relatively protracted and predictable manner, which allows for multiple therapeutic options. Even in the presence of hepatic metastases, the standard of treatment for neuroendocrine malignancy is surgery, either with curative intent or for tumor cytoreduction, i.e., resection of 90% or more of the tumor volume. Image-guided ablation, as either an adjunct to surgery or a primary treatment modality, can be used to treat neuroendocrine cancer metastatic to the liver. Image-guided ablative techniques, including radiofrequency ablation, alcohol injection, and cryoablation, can be used in selected patients to debulk hepatic tumors and improve patient symptoms. Although long-term follow-up data are not available, the surgical literature indicates that significant ablative debulking may improve patient survival. In this review, we discuss metastatic neuroendocrine disease and its treatment options, especially image-guided ablative techniques.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16041556     DOI: 10.1007/s00270-004-4082-6

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  21 in total

1.  CT evaluation of response in advanced gastroenteropancreatic neuroendocrine tumors treated with long-acting-repeatable octreotide: what is the optimal size variation threshold?

Authors:  Yanji Luo; Jie Chen; Bingqi Shen; Meng Wang; Huasong Cai; Ling Xu; Luohai Chen; Minhu Chen; Zi-Ping Li; Shi-Ting Feng
Journal:  Eur Radiol       Date:  2018-06-06       Impact factor: 5.315

Review 2.  Treatment of liver metastases in patients with digestive neuroendocrine tumors.

Authors:  Roberta Elisa Rossi; Sara Massironi; Matilde Pia Spampatti; Dario Conte; Clorinda Ciafardini; Federica Cavalcoli; Maddalena Peracchi
Journal:  J Gastrointest Surg       Date:  2012-07-25       Impact factor: 3.452

Review 3.  Therapy for metastatic pancreatic neuroendocrine tumors.

Authors:  Roberta Elisa Rossi; Sara Massironi; Dario Conte; Maddalena Peracchi
Journal:  Ann Transl Med       Date:  2014-01

Review 4.  Surgical treatment of liver metastases in patients with neuroendocrine tumors.

Authors:  Ahmad Saeed; Joseph F Buell; Emad Kandil
Journal:  Ann Transl Med       Date:  2013-04

5.  Neuroendocrine tumor presenting like lymphoma: a case report.

Authors:  Riccardo Del Vescovo; Roberto Luigi Cazzato; Sofia Battisti; Francesco D'Agostino; Bruno Vincenzi; Rosario Francesco Grasso; Bruno Beomonte Zobel
Journal:  J Med Case Rep       Date:  2011-10-05

6.  Hepatic artery embolization for neuroendocrine tumors: postprocedural management and complications.

Authors:  Mark A Lewis; Sylvia Jaramillo; Lewis Roberts; Chad J Fleming; Joseph Rubin; Axel Grothey
Journal:  Oncologist       Date:  2012-04-17

Review 7.  Insulinoma.

Authors:  Aarti Mathur; Philip Gorden; Steven K Libutti
Journal:  Surg Clin North Am       Date:  2009-10       Impact factor: 2.741

8.  An overview of the surgical management of hepatic neuroendocrine metastases.

Authors:  S Pathak; I Dash; M R Taylor; G J Poston
Journal:  Indian J Surg Oncol       Date:  2012-02-16

9.  Adjunctive radiofrequency ablation of metastatic neuroendocrine cancer to the liver complements surgical resection.

Authors:  Timucin Taner; Thomas D Atwell; Lizhi Zhang; Trynda N Oberg; William S Harmsen; Seth W Slettedahl; Michael L Kendrick; David M Nagorney; Florencia G Que
Journal:  HPB (Oxford)       Date:  2012-07-26       Impact factor: 3.647

10.  Surgery and radiofrequency ablation for treatment of liver metastases from midgut and foregut carcinoids and endocrine pancreatic tumors.

Authors:  John Eriksson; Peter Stålberg; Anders Nilsson; Johan Krause; Christina Lundberg; Britt Skogseid; Dan Granberg; Barbro Eriksson; Göran Akerström; Per Hellman
Journal:  World J Surg       Date:  2008-05       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.